Overview

• Semaglutide, tirzepatide, dulaglutide and liraglutide are listed for adults with type 2 diabetes who also have established cardiovascular disease, chronic kidney disease or obesity.
• WHO did not endorse GLP-1s for obesity as a standalone indication, providing guidance to prioritize patients most likely to benefit.
• WHO flagged high prices as a barrier, urged generic production, and noted key patents begin to expire next year.
• The update brings the Model Lists to 523 adult and 374 pediatric medicines used by more than 150 countries to guide procurement and reimbursement.
• Other additions include Trikafta/Kaftrio for cystic fibrosis, Keytruda and related PD-1/PD-L1 therapies for certain metastatic cancers, and rapid-acting insulin analogues.